熊去氧胆酸的临床应用进展

doi:10.19803/j.1672-8629.20210604

摘要/Abstract

摘要： 熊去氧胆酸(ursodeoxycholic acid,UDCA)是由胆固醇衍生而来的天然亲水性胆汁酸,可通过抑制胆固醇在肠道内的重吸收和降低胆固醇向胆汁中的分泌,从而降低胆固醇的饱和度,临床上主要用于胆石症、胆汁淤积性肝病、胆汁反流性胃炎、原发性硬化性胆管炎等的治疗。本文从UDCA临床应用和指南推荐角度,总结其在疾病的应用、不良反应和药学监护等,为UDCA的临床合理应用提供参考。

关键词: 熊去氧胆酸, 临床应用, 药学监护, 药物治疗

Abstract: Ursodeoxycholic acid is a natural hydrophilic bile acid derived from cholesterol, which can inhibit the reabsorption of cholesterol in the intestine and reduce the secretion of cholesterol into bile. Thereby reducing the saturation of cholesterol, it is mainly used clinically for the treatment of cholelithiasis, cholestatic liver disease, bile reflux gastritis, primary sclerosing cholangitis, etc. This article summarizes the clinical application of ursodeoxycholic acid and the recommendations of the guidelines, summarizes its application in diseases, adverse reactions and pharmaceutical monitoring, etc., and provides a reference for the reasonable clinical application of ursodeoxycholic acid.

Key words: ursodeoxycholic acid, clinical use, pharmaceutical care, drug therapy

中图分类号:

R975

孙雪林, 胡欣, 张亚同. 熊去氧胆酸的临床应用进展[J]. 中国药物警戒, 2022, 19(10): 1149-1153.

SUN Xuelin, HU Xin, ZHANG Yatong. Clinical application of ursodeoxycholic acid[J]. Chinese Journal of Pharmacovigilance, 2022, 19(10): 1149-1153.

参考文献

[1] AERTS R, PENNINCKX F.The burden of gallstone disease in Europe[J]. Aliment Pharmacol Ther, 2003, 18(Suppl 3): 49-53.
[2] YOU GM.Overview of research on ursodeoxycholic acid[J]. Journal of Pharmaceutical Research(药学研究),2021, 40(3):199-202.
[3] DataBase Yaozhi. Ursodeoxycholic Acid Capsules [EB/OL].(2013-06-28)[2022-08-04]. https://db.yaozh.com/directory/6933233860000008.html.
[4] PEERY AF, CROCKETT SD, BARRITT AS, et al.Burden of Gastrointestinal, liver, and pancreatic diseases in the United States[J]. Gastroenterology, 2015, 149(7): 1731-1741.
[5] GUARINO MP, CONG P, CICALA M, et al.Ursodeoxycholic acid improves muscle contractility and inflammation in symptomatic gallbladders with cholesterol gallstones[J]. Gut, 2007, 56(6): 815-820.
[6] Guarino MP, Cocca S, Altomare A, et al.Ursodeoxycholic acid therapy in gallbladder disease, a story not yet completed[J]. World J Gastroenterol, 2013, 19(31): 5029-5034.
[7] RUBIN RA, KOWALSKI TE, KHANDELWAL M, et al.Ursodiol for hepatobiliary disorders[J]. Ann Intern Med, 1994, 121(3): 207-218.
[8] NONE. clinical updates in women's health care summary: liver disease: reproductive considerations[J]. Obstet Gynecol, 2017, 129(1): 236.
[9] GEENES V, WILLIAMSON C.Intrahepatic cholestasis of pregnancy[J]. World J Gastroenterol, 2009, 15(17): 2049-2066.
[10] KREMER AE, OUDE ELFERINK RP, BEUERS U.Pathophysiology and current management of pruritus in liver disease[J]. Clin Res Hepatol Gastroenterol, 2011, 35(2): 89-97.
[11] BICOCCA MJ, SPERLING JD, CHAUHAN SP.Intrahepatic cholestasis of pregnancy: review of six national and regional guidelines[J]. Eur J Obstet Gynecol Reprod Biol, 2018, 231: 180-187.
[12] EATON JE, TALWALKAR JA, LAZARIDIS KN, et al.Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management[J]. Gastroenterology, 2013, 145(3): 521-536.
[13] PAUMGARTNER G, BEUERS U.Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited[J]. Hepatology, 2002, 36(3): 525-531.
[14] CHARATCHAROENWITTHAYA P, ANGULO P, ENDERS FB, et al.Impact of inflammatory bowel disease and ursodeoxycholic acid therapy on small-duct primary sclerosing cholangitis[J]. Hepatology, 2008, 47(1): 133-142.
[15] DE MARIA N, COLANTONI A, ROSENBLOOM E, et al.Ursodeoxycholic acid does not improve the clinical course of primary sclerosing cholangitis over a 2-year period[J]. Hepatogastroenterology, 1996, 43(12): 1472-1479.
[16] SHI J, LI Z, ZENG X, et al.Ursodeoxycholic acid in primary sclerosing cholangitis: meta-analysis of randomized controlled trials[J]. Hepatol Res, 2009, 39(9): 865-873.
[17] KELLY DA.Liver complications of pediatric parenteral nutrition-epidemiology[J]. Nutrition, 1998, 14(1): 153-157.
[18] ARSLANOGLU S, MORO GE, TAUSCHEL HD, et al.Ursodeoxycholic acid treatment in preterm infants: a pilot study for the prevention of cholestasis associated with total parenteral nutrition[J]. J Pediatr Gastroenterol Nutr, 2008, 46(2): 228-231.
[19] CHEN CY, TSAO PN, CHEN HL, et al.Ursodeoxycholic acid (UDCA) therapy in very-low-birth-weight infants with parenteral nutrition-associated cholestasis[J]. J Pediatr, 2004, 145(3): 317-321.
[20] SAN LUIS VA, BTAICHE IF.Ursodiol in patients with parenteral nutrition-associated cholestasis[J]. Ann Pharmacother, 2007, 41(11): 1867-1872.
[21] RANGEL SJ, CALKINS CM, COWLES RA, et al.Parenteral nutrition-associated cholestasis: an American Pediatric Surgical Association Outcomes and Clinical Trials Committee systematic review[J]. J Pediatr Surg, 2012, 47(1): 225-240.
[22] BEUERS U, GERSHWIN ME, GISH RG, et al.Changing nomenclature for PBC: From ‘cirrhosis' to ‘cholangitis'[J]. Hepatology, 2015, 62(5): 1620-1622.
[23] CORPECHOT C, ABENAVOLI L, RABAHI N, et al.Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis[J]. Hepatology, 2008, 48(3): 871-877.
[24] LINDOR KD, BOWLUS CL, BOYER J, et al.Primary Biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver Diseases[J]. Hepatology, 2019, 69(1): 394-419.
[25] CHEN XM, LARUSSO NF.Cryptosporidiosis and the pathogenesis of AIDS-cholangiopathy[J]. Semin Liver Dis, 2002, 22(3): 277-289.
[26] CASTIELLA A, IRIBARREN JA, LÓPEZ P, et al. Ursodeoxycholic acid in the treatment of AIDS-associated cholangiopathy[J]. Am J Med, 1997, 103(2): 170-171.
[27] DEBRAY D, KELLY D, HOUWEN R,et al.Best practice guidance for the diagnosis and management of cystic fibrosis-associated liver disease[J]. J Cyst Fibros, 2011,10(Suppl 2): S29-S36.
[28] SOKOL RJ, DURIE PR.Recommendations for management of liver and biliary tract disease in cystic fibrosis[J]. J Pediatr Gastroenterol Nutr, 1999, 28(Suppl 1): S1-S13.
[29] COLOMBO C.Liver disease in cystic fibrosis[J]. Curr Opin Pulm Med, 2007, 13(6): 529-536.
[30] ZHNG H, HAN J, ZHANG XL.An excerpt of the Japanese society of gastroenterology of evidence-based clinical practice guidelines for liver cirrhosis(2015)[J]. Journal of Clinical Hepatol(临床肝胆病杂志), 2016, 32(9):1659-1663.
[31] YE JF, WU JM, ZHANG BQ, et al.Recommendation for EASL clinical practice guidelines on the prevention, diagnosis, and therapy of gallstones(2016)[J]. Journal of Clinical Hepatol(临床肝胆病杂志), 2016, 32(8): 1446-1449.
[32] SUN CY, MA X.An excerpt of EASL clinical practice guidelines: the diagnosis and management of patients with primary biliary cholangitis(2017)[J]. Journal of Clinical Hepatol(临床肝胆病杂志), 2017, 33(10): 1888-1894.
[33] LI QQ, ZHOU XM, QI XS, et al.Recommendations for the British Society of Gastroenterology/UK-PBC primary biliary cholangtitis treatment and management guidelines(2018)[J]. Journal of Clinical Hepatol(临床肝胆病杂志), 2018, 34(6): 1191-1192.
[34] LU LG, TIAN LY, XU MY, et al, European society of liver disease clinical practice Guidelines: treatment of cholestatic liver disease (3)[J]. Chinese Hepatology(肝脏), 2009, 14(6): 476-478.
[35] LU LG, TIAN LY, XU MY, et al, European Society of Liver Disease clinical Practice Guidelines: Treatment of cholestatic liver disease (2)[J]. Chinese Hepatology(肝脏), 2010, 15(1): 44-48.
[36] YAN H, NIU JQ.ACG clinical guidelines: primary sclerosing cholangtisi(2015)-an excerpt of recommendations[J]. Journal of Clinical Hepatol(临床肝胆病杂志), 2015, 31(8): 1198-1201.
[37] YU YC, HOU JL.ACG clinical guidelines(2016): liver disease and pregnancy[J]. Journal of Clinical Hepatol(临床肝胆病杂志), 2016, 32(4): 619-627.
[38] SUN XD, YE JF, FU Y, et al.American academy of liver diseases and american society of transplantation 2012 practice guidelines: long-term management after successful liver transplantation in adults[J]. Journal of Clinical Hepatol(临床肝胆病杂志), 2013, 29(6): 481-495.
[39] TAN YP.AGA Institute medical position panel on diagnosis and management of colorecatal neoplasia in inflammatory bowel disease[J]. Chin J Gastrointest Surg(中华胃肠外科杂志), 2010, 13(9): 711-712.
[40] Chinese Society of Hepatology, Chinese Medical Association, Chinese Society of Gastroenterology, et al. Expert consensus on diagnosis and Treatment of Primary sclerosing cholangitis (2015)[J]. Journal of Clinical Hepatol(临床肝胆病杂志), 2016, 32(1): 23-31.
[41] Chinese Society of Hepatology, Chinese Medical Association, Chinese Society of Gastroenterology, et al. Consensus on diagnosis and treatment of Primary Biliary cirrhosis (ALSO known as Primary biliary cholangitis) (2015)[J]. Chinese Journal of Hepatology|Chin J Hepatol(中华肝脏病杂志), 2016, 24(1): 5-13.
[42] Committee of Experts of Diagnosis and Treatment of Intrahepatic Cholestasis. Intrahepatic cholestasis diagnosis and treatment expert consensus[J]. Chin J Clin Infect Dis(中华临床感染病杂志), 2015, 8(5): 402-406.
[43] Expert Committee on the 2015 Update of Expert Consensus on the Diagnosis and Treatment of Cholestatic Liver Disease. Expert consensus on the diagnosis and treatment of cholestatic liver disease: an update in 2015 the 2015 Update of Expert Consensus on the Diagnosis and Treatment of Cholestatic Liver Disease. Expert consensus on the diagnosis and treatment of cholestatic liver disease: an update in 2015[J]. Journal of Clinical Hepatol(临床肝胆病杂志), 2015, 31(10): 1563-1574.
[44] Department of Obstetrics and Gynecology, Chinese Medical Association. Guidelines for the diagnosis and treatment of intrahepatic cholestasis of pregnancy (2015)[J]. Chin J Obstet Gynecol(中华妇产科杂志), 2015, 50(7): 481-485.
[45] LI JX, CHEN Y, LIANG J.Consensus on integrated traditional Chinese and Western medicine diagnosis and treatment of cholelithiasis (2017)[J]. Chinese Journal of Integrated Traditional and Western Medicine on Digestion(中国中西医结合消化杂志), 2018, 26(2): 132-138.
[46] CHEN YB, HUANG WM, HUANG L, et al.Expert suggestions on standardized medicationguidance for neonatal jaundice[J]. Chin Med Herald(中国医药导报), 2019, 16(27): 105-110.
[47] Editorial Board of Chinese Journal of Digestion, Cooperation Group of Hepatobiliary Diseases of Chinese Society of Gastroenterology. Consensus on diagnosis and treatment of chronic cholecystitis and gallstones in China(2018)[J]. Chin J Dig(中华消化杂志), 2019, 35(6): 1231-1236.
[48] Neonatal Surgery Group, Pediatric Hepatobiliary Surgery Group, Pediatric Pediatric Surgery Branch, et al. Diagnosis and treatment of biliary atresia in mainland China (expert consensus)[J]. Chin J Pediatr Surg(中华小儿外科杂志), 2013, 34(9): 700-705.
[49] HU ZC, NI P, FAN L, et al.Past hepatitis B virus infection was not associated with poorer response or the UK-PBC risk score in ursodeoxycholic acid-treated patients with primary biliary cirrhosis[J]. Eur J Gastroenterol Hepatol, 2019, 31(2): 277.
[50] ZHOU XL, FU JF.Expert consensus on the diagnosis and treatment of nonalcoholic fatty disease in children[J]. Chinese Journal of Practical Pediatrics(中国实用儿科杂志), 2018, 33(7): 487-492.
[51] Digestive Diseases Professional Committee of Chinese Association of Integrated Traditional and Western Medicine. Consensus on diagnosis and treatment of cirrhotic ascites with integrated Traditional Chinese and Western medicine[J]. Chinese Journal of Integrated Traditional and Western Medicine(中国中西医结合杂志), 2011, 31(9): 1171-1174.
[52] XIAO XH, LI XH, ZHU Y.Guidelines for diagnosis and treatment of herb-induced liver injury[J]. China Journal of Chinese Materia Mdica(中国中药杂志), 2016, 41(7): 1165-1172.
[53] Chinese Society of Infectious Diseases, Chinese Medical Association. Expert consensus on diagnosis and treatment of end-stage liver disease with infection (2021 edition)[J]. Chin J Hepatol(中华肝脏病杂志), 2022, 30(2): 147-158.
[54] CHEN XP, MAO YL, QIU YD, et al.Expert consensus on perioperative management of hepatectomy[J]. Chinese Journal of Practical Surgery(中国实用外科杂志), 2017, 37(5): 525-530.
[55] WANG YM, YU YC.Liver inflammation and its prevention and cure expert consensus[J]. Chin J Infect(中华肝脏病杂志), 2014, 22(2): 94-103.
[56] Tuberculosis Branch of Chinese Medical Association. Guidelines for the diagnosis and treatment of antituberculous drug-induced liver injury (2019 Edition)[J]. Chinese Journal of Tuberculosis and Respiratory Diseases(中华结核和呼吸杂志), 2019, 42(5): 343-356.
[57] Hepatobiliary Diseases Association of Gastroenterology Society of Chinese Medical Association. Recommendations on diagnosis and treatment of Acute Drug-induced Liver Injury (draft)[J]. Chin J Dig(中华消化杂志), 2007, 27(11): 765-767.
[58] Chinese Lapatinib Adverse Response Management Consensus Expert Group. Consensus on adverse reaction management of Lapatinib[J]. Oncology Process(癌症进展), 2019, 17(22): 2605-2611.
[59] Chinese Society of Hepatology Chinese Medical Association, Chinese Society of Gastroenterology Chinese Medical Association, Chinese Society of Infectious Diseases, et alConsensus on diagnosis and treatment of hepatic fibrosis in 2019[J]. Chin J Hepatol(中华肝脏病杂志), 2019, 27(9): 657-667.
[60] Chinese Society of Hepatology, Chinese Medical Association, Chinese Society of Gastroenterology, et al. Consensus on the diagnosis and management of autoimmune hepatitis(2015)[J]. Chin J Hepatol(中华肝脏病杂志), 2016, 24(1): 23-35.
[61] SHI JP, FAN JG.Expert recommendation on standardized diagnosis and treatment for fatty liver disease(2019 revised edition)[J]. Journal of Practical Hepatology(实用肝脏病杂志), 2019, 22(6): 787-792.
[62] YOU GM.Overview of research on ursodeoxycholic acid[J]. Journal of Pharmaceutical Research(药学研究), 2021, 40(3): 199-202.
[63] FDA. FDA-Approved Drugs. URSO 250[EB/OL].(2013-06-14)[2022-08-04]. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020675.
[64] SHI YH.Ursodeoxycholic acid and interstitial pneumonia[J]. Adverse Drug Reaction Journal(药物不良反应杂志), 2001, 3(4): 266-266.